Iceland· IS-EU/1/15/1043/001-002
Nucala
A mepolizumab product containing mepolizumabum inn, registered in Iceland by GlaxoSmithKline Trading Services Limited. The same ATC class is registered in 13 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Mepolizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC R03DX09 (mepolizumab), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Mepolizumab · ATC R03DX09
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Mepolizumabum INN
- Manufacturer
- GlaxoSmithKline Trading Services Limited
- Country
- Iceland (IS)
- ATC code
- R03DX09
- ATC class
- Mepolizumab
- Defined daily dose
- 3.6 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean4788081 pennar x1 pakkiISK 177698
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mepolizumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaNUCALAGlaxoSmithKline Trading Services Limited, Dublin
- BelgiumNucala 100 mgGlaxoSmithKline Trading Services
- SpainNUCALA 100 MG POLVO PARA SOLUCION INYECTABLEGlaxosmithkline Trading Services Limited
- United KingdomNucala 100mg powder for solution for injection vialsGlaxoSmithKline UK Ltd
- PolandNucalaGlaxoSmithKline Trading Services Limited
- SwedenNucala 100 mg Pulver till injektionsvätska, lösningGlaxoSmithKline Trading Services Ltd
- ItalyNUCALA*1 flaconcino SC 100 mgGLAXOSMITHKLINE TRAD.SERV.LTD
- FinlandNucalaGlaxoSmithKline Trading Services Limited
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Nucala
- Norway · Nucala
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e12d76a9-5416-4eef-882f-765957872ef1 GET /v1/drugs/e12d76a9-5416-4eef-882f-765957872ef1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stungulyfsstofn, lausn",
"source": "lyfjastofnun",
"atc_raw": "R03DX09",
"marketed": false,
"strength": "100 mg",
"ma_number": "EU/1/15/1043/001-002",
"substance": "Mepolizumabum INN",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í lungnalækningum, ofnæmislækningum, ónæmisfræði og háls-, nef- og eyrnalækningum.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "42340"
}See everything about mepolizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.